Nuvation Bio Inc.

Nuvation Bio Inc. is a global oncology company dedicated to developing therapies for some of the most challenging cancers. Founded in 2018 by biopharma veteran David Hung, M.D., the company's mission is to create a profound, positive impact on patients' lives by pursuing innovative approaches in cancer treatment. Nuvation Bio maintains dual headquarters in New York, NY, and San Francisco, CA, with additional operational presence in Boston and Shanghai.

The company focuses on developing and commercializing targeted cancer therapies, primarily utilizing small molecule inhibitors and proprietary drug-drug conjugates (DDCs) for genomically defined cancers. Its pipeline features key candidates such as IBTROZI (taletrectinib), a next-generation ROS1 inhibitor for ROS1-positive non-small cell lung cancer (NSCLC), and safusidenib, a brain-penetrant IDH1 inhibitor for IDH1-mutant glioma. Nuvation Bio transitioned into a commercial-stage entity in June 2025 following the U.S. FDA approval of IBTROZI.

Nuvation Bio has successfully evolved from a clinical-stage biotech to a commercial organization, largely driven by the launch of IBTROZI. In April 2026, taletrectinib (IBTROZI) was added to the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines for Central Nervous System (CNS) cancers, recognizing its efficacy in ROS1-positive NSCLC patients with brain metastases. The company is led by its Founder, President, and CEO, David Hung, M.D. As of late 2025, Nuvation Bio reported a trailing 12-month revenue of $62.9 million and held a market capitalization of approximately $1.56 billion as of May 2026.